Compare SOTK & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | ASRT |
|---|---|---|
| Founded | 1975 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.7M | 75.1M |
| IPO Year | 1987 | 1997 |
| Metric | SOTK | ASRT |
|---|---|---|
| Price | $4.14 | $11.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 25.1K | ★ 69.5K |
| Earning Date | 01-13-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | $20,420,804.00 | ★ $137,354,000.00 |
| Revenue This Year | $2.67 | N/A |
| Revenue Next Year | $8.20 | N/A |
| P/E Ratio | $42.30 | ★ N/A |
| Revenue Growth | 1.34 | ★ 9.22 |
| 52 Week Low | $3.23 | $7.71 |
| 52 Week High | $5.15 | $15.15 |
| Indicator | SOTK | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 52.36 | 87.55 |
| Support Level | $4.02 | $9.11 |
| Resistance Level | $4.37 | $10.39 |
| Average True Range (ATR) | 0.20 | 0.61 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 30.44 | 91.03 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.